Focal and generalized bone loss in rheumatoid arthritis: Separate or similar concepts?

Nature Clinical Practice Rheumatology

Volumn 4, Issue 8, 2008, Pages 402-403

  Haugeberg, Glenn ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; DENOSUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; ZOLEDRONIC ACID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE EROSION; BONE RADIOGRAPHY; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE RESORPTION; HUMANS; OSTEOPOROSIS;

EID: 48749116547     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0843     Document Type: Article

References (14)

1. Sambrook PN (2000) The skeleton in rheumatoid arthritis: Common mechanisms for bone erosion and osteoporosis? J Rheumatol 27 2541-2542
2. Redlich K et al. (2002) Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110: 1419-1427
3. Pettit AR et al. (2001) TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159: 1689-1699
4. Jarrett SJ et al. (2006) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54: 1410-1414
5. Schett G et al. (2005) Mechanisms of Disease: The link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 1 47-54
6. Vis M et al. (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65: 1495-1499
7. Hoff M et al. (2007) Anti-TNF treatment with adalimumab reduces hand bone loss in early rheumatoid arthritis (RA): Explorative analyses from the PREMIER study [abstract #268] Arthritis Rheum 56 (Suppl): S152-S153. Presented at the ACR/ARHP Annual Scientific Meeting: 2007 November 6-11, Boston, MA
8. Breedveld FC et al. (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37
9. Haugeberg G et al. (2005) Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: Results from a randomized placebo-controlled trial. Arch Intern Med 165: 1293-1297
10. van der Heijde D et al. (2007) Denosumab inhibits RANKL, reducing progression of the total Sharp score and bone erosions in patients with rheumatoid arthritis: 12-month X-ray results [abstract #698]. Arthritis Rheum 56 (Suppl): S299-S300. Presented at the ACR/ARHP Annual Scientific Meeting: 2007 November 6-11, Boston, MA
11. Haugeberg G and Emery P (2005) Value of dual-energy X-ray absorptiometry as a diagnostic and assessment tool in early rheumatoid arthritis. Rheum Dis Clin North Am 31: 715-728
12. Haugeberg G et al. (2006) Hand bone loss in early undifferentiated arthritis: Evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 65: 736-740
13. Hoff M et al. (2008) Cortical hand bone loss after one year in early rheumatoid arthritis predicts radiographic hand joint damage at 5 and 10 year follow-up. Ann Rheum Dis [doi:10.1136/ard.2007.085985]
14. Haugeberg G et al. (2007) Hand bone densitometry: A more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Ann Rheum Dis 66: 1513-1517